Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

iBio (IBIO) Cost of Revenue (2020 - 2022)

iBio (IBIO) has disclosed Cost of Revenue for 3 consecutive years, with $15000.0 as the latest value for Q2 2022.

  • Quarterly Cost of Revenue fell 91.98% to $15000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $216000.0 through Jun 2022, down 78.36% year-over-year, with the annual reading at $216000.0 for FY2022, 85.23% down from the prior year.
  • Cost of Revenue for Q2 2022 was $15000.0 at iBio, down from $48000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $493000.0 in Q1 2021, with the low at $15000.0 in Q2 2022.
  • Average Cost of Revenue over 3 years is $159900.0, with a median of $110000.0 recorded in 2020.
  • The sharpest move saw Cost of Revenue surged 473.26% in 2021, then tumbled 91.98% in 2022.
  • Over 3 years, Cost of Revenue stood at $211000.0 in 2020, then plummeted by 46.45% to $113000.0 in 2021, then tumbled by 86.73% to $15000.0 in 2022.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $15000.0, $48000.0, and $113000.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.